T. Dyulgerov

T. Dyulgerov

Auto-generated profile, based on publicly available information

T. Dyulgerov

Department of Psychiatry , “Aleksandrovska” University Hospital, Medical University – Sofia , Bulgaria

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Acta Medica Bulgarica
Verified
Journal Article
Open access
PDF file
KAK. Angelov
K. Angelov
NNN. Nachev
N. Nachev
EYE. Yordanov
E. Yordanov
SSS. Stoyanova
S. Stoyanova
NKN. Khayat
N. Khayat
TDT. Dyulgerov
T. Dyulgerov
Gastric carcinoma poses a significant clinical challenge and remains one of the leading causes of cancer-related mortality worldwide. Accurate classification of these tumors based on their histology, anatomical location, and molecular characteristics is essential, as it dictates both prognosis and therapeutic strategy. Objective: to review the key classification systems that underpin the current understanding and treatment of gastric cancer, and to analyze new approaches to diagnosis and treatment through a systematic review of scientific publications. Materials and Methods: we conducted a scoping review by searching for scientific publications in various sources – databases and printed literature, articles, textbooks, monographs, etc. Results and Discussion: Lauren’s histological classification distinguishes between intestinal and diffuse types, which have different etiologies and prognoses. The anatomical location, especially the distinction between cardia and non-cardia cancer, is also important. The evolving under-standing of its biology, including the key role of H. pylori, hereditary syndromes, such as HDGC, and the clinical significance of TCGA molecular subtypes, has been changing the epidemiological landscape and shaping the current paradigm of multidisciplinary, mul-timodal treatment. Radical surgical treatment and adequate lymph node dissection determine the outcome of the disease. Advances in perioperative systemic treatments and a personalized approach based on biomarkers, such as MSI status for immunotherapy, improve treatment outcomes.

1 February 2026 in Acta Medica Bulgarica
Verified
Journal Article
Open access
PDF file
KAK. Angelov
K. Angelov
NNN. Nachev
N. Nachev
EYE. Yordanov
E. Yordanov
SSS. Stoyanova
S. Stoyanova
ARAntoan Rangelov
Antoan Rangelov
TDT. Dyulgerov
T. Dyulgerov
Small intestine cancer encompasses a group of malignant diseases originating in the duodenum, jejunum, or ileum. Although they account for only 3-5% of all gas-trointestinal carcinomas, their incidence is increasing, unlike more common malignant diseases, such as colorectal carcinoma, which makes their study increasingly important. Objective: to analyze the main malignant histological subtypes – adenocarcinomas, neuroendocrine neoplasms, gastrointestinal stromal tumors, and lymphomas – and to summarize and systematize the available literature data. Materials and Methods: We applied a narrative review study design involving the summarization and interpretation of existing literature data on the given topic and objective in order to create a structured, comprehensive scientific product on malignant diseases of the small intestine. We analyzed 20 literature sources. Results and Discussion: The etiology of small intestine cancer is multifactorial and can be divided into well-defined hereditary cancer syndromes and acquired chronic inflammatory conditions. Malignant tumors of the small intestine are a rare but increasingly common group of diseases that are difficult to manage due to their heterogeneity. This biological heterogeneity requires highly specific diagnostic, surgical, and systemic (e.g., targeted therapy for GIST, immunotherapy for MSI-H SBA, PRRT with 177Lu-DOTATATE for NETs) management strategies. Optimal results for the treatment of these rare tumors require a specialized, multidisciplinary approach, concentrated in high-tech centers and institutions.

1 February 2026 in Acta Medica Bulgarica
Verified
Journal Article
Open access
PDF file
KAK. Angelov
K. Angelov
NNN. Nachev
N. Nachev
EYE. Yordanov
E. Yordanov
ARAntoan Rangelov
Antoan Rangelov
EHE. Hristov
E. Hristov
TDT. Dyulgerov
T. Dyulgerov
Globally, pancreatic cancer continues to be a significant health problem. The number of new cases has been increasing by an average of 0.8% per year over the last decade. The prognosis remains extremely poor, with a five-year survival rate of 7.2%, confirming its reputation as one of the deadliest malignant diseases. Objective: to ana-lyze recent developments in the management of the diagnostic and treatment process for pancreatic cancer. Materials and Methods: systematic review of scientific publications through documentary analysis and analysis of the content of scientific publications selected by predefined key words. Results and Discussion: pancreatic cancer is one of the greatest clinical challenges in modern oncology, characterized by an extremely high mortality rate. Due to the lack of specific early manifestations and the biological aggressiveness of the disease, diagnosis is delayed in more than 80% of cases. Pancreatic disease should always be considered in the differential diagnosis of any acute or chronic pain. Successful management of these complex tumors requires a nuanced, multidisciplinary approach that integrates precise diagnosis, staging, and individualized therapeutic strategies.

1 February 2026 in Acta Medica Bulgarica
Verified
Journal Article
Open access
PDF file
KAK. Angelov
K. Angelov
SSS. Stoyanova
S. Stoyanova
EYE. Yordanov
E. Yordanov
IPI. Parvova
I. Parvova
NKN. Khayat
N. Khayat
TDT. Dyulgerov
T. Dyulgerov
Cancers of the gallbladder and bile ducts, although relatively rare, are highly lethal malignant diseases due to their aggressive biology, complex hilar and retroperito-neal anatomy, and frequently delayed diagnosis. Objective: To analyze the latest developments in the integration of immunotherapy and targeted agents in the treatment of gall-bladder and bile duct cancers. Materials and Methods: Review of scientific publications using documentary analysis and content analysis. Results and Discussion: Gallbladder and bile duct cancer are aggressive malignant diseases with increasing incidence, especially for intrahepatic cholangiocarcinoma. Although surgery remains the primary treatment method, the integration of immunotherapy and targeted agents based on molecular profiling is transforming the therapeutic landscape and offering new hope for patients with advanced disease.

1 February 2026 in Acta Medica Bulgarica
Verified
Journal Article
Open access
PDF file
KAK. Angelov
K. Angelov
SSS. Stoyanova
S. Stoyanova
EYE. Yordanov
E. Yordanov
IPI. Parvova
I. Parvova
NKN. Khayat
N. Khayat
TDT. Dyulgerov
T. Dyulgerov
Hepatocellular carcinoma accounts for approximately 90% of all primary liver cancers and is a major cause of cancer-related mortality worldwide, ranking second among the most common causes of cancer death. Primary liver cancer is defined as a malignant neoplasm originating from cells in the liver, including hepatocytes, cholangio-cytes, or their progenitor cells. Objective: to analyze the latest developments in locore-gional techniques and systemic and multimodal treatment of primary liver tumors. Materials and Methods: systematic review of scientific publications through documentary analysis and content analysis of scientific publications selected by predefined key words. Results and Discussion: over the last decade, there has been a paradigm shift in the treatment of primary liver cancer. The integration of transarterial therapies, targeted agents, and immune checkpoint inhibitors has significantly prolonged survival and transformed the therapeutic landscape. These advances require complex, multidisciplinary decisions regarding the sequence of therapies and patient management. Advances in molecular biology have transformed therapeutic approaches, particularly in ICC, where treatment is now guided by biomarkers, and in HCC, where immunotherapeutic combinations have set a new standard of care.